JP2016539168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539168A5 JP2016539168A5 JP2016536746A JP2016536746A JP2016539168A5 JP 2016539168 A5 JP2016539168 A5 JP 2016539168A5 JP 2016536746 A JP2016536746 A JP 2016536746A JP 2016536746 A JP2016536746 A JP 2016536746A JP 2016539168 A5 JP2016539168 A5 JP 2016539168A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- steps
- following
- synthesizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 238000000034 method Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 4
- 230000002194 synthesizing effect Effects 0.000 claims 3
- 239000000543 intermediate Substances 0.000 claims 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 1
- 0 CCCc(cc1C*C)ccc1N Chemical compound CCCc(cc1C*C)ccc1N 0.000 description 2
- WUTVUNYCKGJXHV-UHFFFAOYSA-N Cc(cc1C=O)ccc1N Chemical compound Cc(cc1C=O)ccc1N WUTVUNYCKGJXHV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195864 | 2013-12-05 | ||
| EP13195864.7 | 2013-12-05 | ||
| PCT/EP2014/076041 WO2015082370A1 (en) | 2013-12-05 | 2014-12-01 | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539168A JP2016539168A (ja) | 2016-12-15 |
| JP2016539168A5 true JP2016539168A5 (enExample) | 2018-08-09 |
| JP6454707B2 JP6454707B2 (ja) | 2019-01-16 |
Family
ID=49726573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536746A Active JP6454707B2 (ja) | 2013-12-05 | 2014-12-01 | ｔｒａｎｓ−８−クロロ−５−メチル−１−［４−（ピリジン−２−イルオキシ）−シクロヘキシル］−５，６−ジヒドロ−４Ｈ−２，３，５，１０ｂ−テトラアザ−ベンゾ［ｅ］アズレン及びその結晶形態の合成 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10246460B2 (enExample) |
| EP (1) | EP3077396B1 (enExample) |
| JP (1) | JP6454707B2 (enExample) |
| KR (3) | KR102384629B1 (enExample) |
| CN (1) | CN105793263B (enExample) |
| AR (1) | AR098592A1 (enExample) |
| AU (2) | AU2014359409A1 (enExample) |
| CA (2) | CA3142754C (enExample) |
| ES (1) | ES2875411T3 (enExample) |
| HR (1) | HRP20210966T1 (enExample) |
| IL (2) | IL245450A0 (enExample) |
| MX (1) | MX372971B (enExample) |
| MY (1) | MY175464A (enExample) |
| NZ (1) | NZ720340A (enExample) |
| PL (1) | PL3077396T3 (enExample) |
| SG (1) | SG11201604502SA (enExample) |
| SI (1) | SI3077396T1 (enExample) |
| WO (1) | WO2015082370A1 (enExample) |
| ZA (1) | ZA201603304B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20210966T1 (hr) | 2013-12-05 | 2021-09-17 | F. Hoffmann - La Roche Ag | Sinteza trans-8-kloro-5-metil-1-[4-(piridin-2-iloksi)-cikloheksil]-5,6-dihidro-4h-2,3,5,10b-tetraazabenzo[e]azulena i njegovih kristalnih oblika |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| TWI816718B (zh) | 2017-12-08 | 2023-10-01 | 瑞士商赫孚孟拉羅股份公司 | 醫藥調配物 |
| WO2020139670A1 (en) | 2018-12-27 | 2020-07-02 | Teva Pharmaceuticals International Gmbh | Solid state forms of balovaptan |
| US20240154207A1 (en) | 2021-10-06 | 2024-05-09 | Lg Energy Solution, Ltd. | Battery module |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1197242A (en) * | 1983-03-02 | 1985-11-26 | Jean A. Gauthier | Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives |
| DE602004003914T2 (de) * | 2003-02-19 | 2007-05-31 | Pfizer Inc. | Für die therapie geeignete triazolverbindungen |
| GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| WO2006021882A1 (en) | 2004-08-25 | 2006-03-02 | Pfizer Limited | Triazolobenzodiazepines and their use as vasopressin antagonists |
| US7601715B2 (en) * | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| KR101385433B1 (ko) * | 2008-11-18 | 2014-04-14 | 에프. 호프만-라 로슈 아게 | 다이하이드로테트라아자벤조아줄렌의 알킬사이클로헥실에터 |
| DK2370441T3 (da) * | 2008-11-28 | 2013-10-21 | Hoffmann La Roche | Arylcyclohexylethere af dihydrotetraazabenzoazulener til anvendelse som vasopressin v1a-receptorantagonister |
| US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| CN105492010B (zh) | 2013-08-19 | 2020-01-03 | 豪夫迈·罗氏有限公司 | 用于治疗相移睡眠障碍的V1a拮抗剂 |
| HRP20210966T1 (hr) * | 2013-12-05 | 2021-09-17 | F. Hoffmann - La Roche Ag | Sinteza trans-8-kloro-5-metil-1-[4-(piridin-2-iloksi)-cikloheksil]-5,6-dihidro-4h-2,3,5,10b-tetraazabenzo[e]azulena i njegovih kristalnih oblika |
-
2014
- 2014-12-01 HR HRP20210966TT patent/HRP20210966T1/hr unknown
- 2014-12-01 SI SI201431838T patent/SI3077396T1/sl unknown
- 2014-12-01 MX MX2016006558A patent/MX372971B/es active IP Right Grant
- 2014-12-01 WO PCT/EP2014/076041 patent/WO2015082370A1/en not_active Ceased
- 2014-12-01 AU AU2014359409A patent/AU2014359409A1/en not_active Abandoned
- 2014-12-01 MY MYPI2016000870A patent/MY175464A/en unknown
- 2014-12-01 NZ NZ720340A patent/NZ720340A/en unknown
- 2014-12-01 KR KR1020217034768A patent/KR102384629B1/ko active Active
- 2014-12-01 PL PL14805290T patent/PL3077396T3/pl unknown
- 2014-12-01 CN CN201480065960.4A patent/CN105793263B/zh active Active
- 2014-12-01 SG SG11201604502SA patent/SG11201604502SA/en unknown
- 2014-12-01 CA CA3142754A patent/CA3142754C/en active Active
- 2014-12-01 KR KR1020167017925A patent/KR102384608B1/ko active Active
- 2014-12-01 JP JP2016536746A patent/JP6454707B2/ja active Active
- 2014-12-01 EP EP14805290.5A patent/EP3077396B1/en active Active
- 2014-12-01 ES ES14805290T patent/ES2875411T3/es active Active
- 2014-12-01 CA CA2931016A patent/CA2931016C/en active Active
- 2014-12-01 KR KR1020217034765A patent/KR102384630B1/ko active Active
- 2014-12-03 AR ARP140104488A patent/AR098592A1/es unknown
-
2016
- 2016-05-03 IL IL245450A patent/IL245450A0/en unknown
- 2016-05-16 ZA ZA2016/03304A patent/ZA201603304B/en unknown
- 2016-06-03 US US15/172,542 patent/US10246460B2/en active Active
-
2019
- 2019-02-18 IL IL264891A patent/IL264891B/en active IP Right Grant
- 2019-02-20 AU AU2019201183A patent/AU2019201183B2/en active Active
- 2019-03-04 US US16/291,887 patent/US11040977B2/en active Active
-
2021
- 2021-06-03 US US17/337,547 patent/US12459947B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019194236A5 (enExample) | ||
| JP2018024670A5 (enExample) | ||
| JP2018536572A5 (enExample) | ||
| JP2018521020A5 (enExample) | ||
| JP2009149903A5 (enExample) | ||
| JP2016520672A5 (enExample) | ||
| JP2013532130A5 (enExample) | ||
| IL256624A (en) | Pharmaceuticals and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| JP2018024682A5 (enExample) | ||
| JP2019048806A5 (enExample) | ||
| JP2016153424A5 (enExample) | ||
| JP2012107057A5 (enExample) | ||
| JP2012111758A5 (enExample) | ||
| JP2011527560A5 (enExample) | ||
| JP2015063536A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| JP2018030858A5 (enExample) | ||
| JP2016539168A5 (enExample) | ||
| JP2019089762A5 (enExample) | ||
| JP2014526533A5 (enExample) | ||
| JP2018150298A5 (enExample) | ||
| JP2015129106A5 (enExample) | ||
| JP2016513122A5 (enExample) | ||
| WO2016038628A3 (en) | A process for preparing olodaterol and intermediates thereof |